MedTech Innovator 2017 Finale FROM LEFT: Paul Leake, VerteCore, JLABS award winner; Albert Huang, Allotrope Medical, finals runner-up; Bradley Messmer, Abreos Biosciences, finalist; Venk Varadan,... Read More →
Vyaire Medical, Inc., the healthcare industry’s dedicated “breathing company,” today announced it has acquired Revolutionary Medical Devices, Inc. (RMD), of Tucson, Ariz., a maker of innovative products for airway management, focused on significantly improving patient outcomes.
Catheter developer Spinal Singularity raised $3.1 million in a seed funding round to support its Connected Catheter designed for adult males with chronic lower urinary tract dysfunction. The funding round was led by Baker & Eastlack Ventures and joined by Western Technology Investments, YCombinator, Santa Barbara Angels, OC Service Academy Anges, SV Tech Ventures, Storm Industries, Particular Ventures, IverNet Holdings and other angel investors.
In the joint research project, the Netherlands Cancer Institute, University of Twente and industry partners, Lightpoint Medical and Philips will evaluate a novel molecular imaging technology to image the prostate cancer biomarker Prostate Specific Membrane Antigen (PSMA) during surgery.
There are three million surgical procedures each year (in the US) in which there is a risk of injuring the ureter, and rates of injury are highest in minimally invasive cases, where up to 30% of OR time can be spent on trying to identify the ureter to spare it from harm. Allotrope Medical has developed an intuitive, battery-operated, single-use handheld device to help surgeons see the location of this hidden part of the anatomy.
Augmedics, a developer of an augmented-reality (AR) surgical visualization system, has secured $8.3 million in Series A funding. Led by Davos, Switzerland-based AO Invest, which is fully funded by the non-profit AO Foundation, as well as Israeli Innovation Authority, Terra Venture Partners and other undisclosed investors. Augmedics will use the proceeds to complete research and development as well as pre-clinical and clinical trials of its ViZOR System, establish strategic distribution partnerships, and seek 510(k) clearance for The ViZOR from the US. Food and Drug Administration.